文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

2025年南半球流感疫苗预防流感相关门诊和住院疾病的 interim 有效性估计——八个南半球国家,2025年3月至9月

Interim Effectiveness Estimates of 2025 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Outpatient and Hospitalized Illness - Eight Southern Hemisphere Countries, March-September 2025.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2025-09-25

利用八个南半球国家流感样疾病和严重急性呼吸道感染哨点监测数据,采用检测阴性病例对照设计估计2025年3月至9月流感疫苗 interim 有效性。任何流感病毒相关门诊就诊和住院的调整后疫苗有效性分别为50.4%和49.7%,甲型流感病毒分别为45.4%和46.1%,主要亚型A(H1N1)pdm09相关住院为41.6%。这些 interim 估计提示疫苗接种使八个南半球国家就医的流感相关疾病减少约一半,卫生当局应优先为所有≥6月龄符合条件者接种疫苗。

要点

  • 任何流感病毒相关门诊就诊的调整后疫苗有效性为50.4%,住院为49.7%。
  • 甲型流感病毒相关门诊就诊和住院的调整后疫苗有效性分别为45.4%和46.1%。
  • 主要亚型A(H1N1)pdm09相关住院的调整后疫苗有效性为41.6%。

核心结论

  • 这些 interim 估计提示疫苗接种使八个南半球国家就医的流感相关疾病减少约一半。
  • 卫生当局应优先为所有≥6月龄符合条件者接种疫苗以减少流感疾病发病率。

研究设计与样本

  • 利用八个南半球国家流感样疾病和严重急性呼吸道感染哨点监测网络数据,采用检测阴性病例对照研究设计估计 interim 疫苗有效性。
  • 2025年3月至9月,澳大利亚和南非识别了2122例流感样疾病患者。
  • 阿根廷、澳大利亚、巴西、智利、新西兰、巴拉圭和乌拉圭识别了42752例严重急性呼吸道感染患者。

主要发现

  • 流感样疾病患者中21.3%接种了流感疫苗,严重急性呼吸道感染患者中15.9%接种了流感疫苗。
  • 任何流感病毒相关门诊就诊的调整后疫苗有效性为50.4%,住院为49.7%。
  • 甲型流感病毒相关门诊就诊的调整后疫苗有效性为45.4%,住院为46.1%。
  • 主要亚型A(H1N1)pdm09相关住院的调整后疫苗有效性为41.6%。

临床怎么用

  • 卫生当局应优先为所有≥6月龄符合条件者接种疫苗以减少流感疾病发病率。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Seasonal influenza vaccination provides important protection from influenza illness and associated potential complications. Monitoring seasonal influenza vaccine effectiveness (VE) in Southern Hemisphere countries can apprise health authorities in Northern Hemisphere countries about the potential protection provided from vaccination. Using data from influenza-like illness (ILI) and severe acute respiratory infection (SARI) sentinel surveillance networks in eight Southern Hemisphere countries, investigators estimated interim VE against influenza-associated outpatient visits and hospitalization using a test-negative case-control study design. During March-September 2025, Australia and South Africa identified 2,122 patients with ILI; Argentina, Australia, Brazil, Chile, New Zealand, Paraguay, and Uruguay identified 42,752 patients with SARI. Overall, 21.3% of patients with ILI and 15.9% of patients with SARI were vaccinated against influenza. Adjusted VE against influenza-associated outpatient visits and hospitalization was 50.4% and 49.7%, respectively, for any influenza virus, and 45.4% and 46.1%, respectively, for influenza A viruses. Adjusted VE against hospitalization with the predominant influenza subtype, A(H1N1)pdm09, was 41.6%. These interim estimates suggest that vaccination reduced medically attended influenza-associated illness by approximately one half in eight Southern Hemisphere countries. Health authorities should prioritize vaccination of all eligible persons ≥6 months to reduce incidence of influenza disease.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Russ S, Nogareda F, Regan AK, et al. Interim Effectiveness Estimates of 2025 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Outpatient and Hospitalized Illness - Eight Southern Hemisphere Countries, March-September 2025. MMWR Morb Mortal Wkly Rep. 2025. PMID: 40996960. doi:10.15585/mmwr.mm7436a3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。